ANTIBODY MEDIATED REJECTION IN KIDNEY TRANSPLANTATION PUBLIC WORKSHOP—April 12 and 13, 2017

Speakers and Panelists

Renata Albrecht, MD
Director, Division of Ophthalmology and Transplant Products (DTOP)
Office of Antimicrobial Products (OAP)
Center for Drug Evaluation and Research (CDER), FDA, Silver Spring, MD

Rita Alloway, PharmD
Research Professor of Medicine
Director, Transplant Clinical Research
University of Cincinnati, Cincinnati, OH

Shukal Bala, PhD
Microbiologist, Division of Anti-Infective Products
CDER, FDA, Silver Spring, MD

Ozlem Belen MD, MPH
Deputy Director for Safety, DTOP
CDER, FDA, Silver Spring, MD

Marc Cavaillé-Coll, MD, PhD
Medical Officer, DTOP
CDER, FDA, Silver Spring, MD

Lakhmir Chawla MD
Professor of Medicine
Veterans Affairs Medical Center, Washington D.C.

Anita S. Chong, PhD
Professor of Surgery, Department of Surgery
University of Chicago, Chicago, IL

Robert B. Colvin, MD
Benjamin Castleman Distinguished Professor of Pathology
Massachusetts General Hospital
Harvard Medical School, Boston, MA

Edward Cox, MD, MPH
Director, Office of Antimicrobial Products
CDER, FDA, Silver Spring, MD
Arjang Djamali, MD
Professor of Medicine and Surgery
Head, Nephrology Division
UW School of Medicine and Public Health, Madison, WI

Dawn Edwards
Patient Representative/ Speaker

Robert S. Gaston, MD
Director, Comprehensive Transplant Institute
Robert G. Luke Endowed Chair in Transplant Nephrology
University of Alabama at Birmingham, Birmingham, AL

Howard M. Gebel, PhD
Professor, Department of Pathology
Emory University Hospital, Atlanta, GA

Mark Haas, MD, PhD
Professor of Pathology
Senior Attending Pathologist
Cedars-Sinai Medical Center, Los Angeles, CA

William Irish, PhD
Vice President-Outcomes Research and Biostatistics
CTI Clinical Trial and Consulting Services, Raleigh NC

Stuart J. Knechtle, MD
Mary and Deryl Hart Professor of Surgery
Executive Director, Duke Transplant Center
Duke University School of Medicine, Durham, NC

Gregory Knoll, MD, MSc
Professor of Medicine, Division of Nephrology
University of Ottawa, Ottawa, Ontario, Canada

Jack Lennon
Patient Representative/ Speaker

Roslyn B. Mannon, MD
Professor of Medicine, Division of Nephrology
Professor of Surgery, Division of Transplantation
Director of Research, Comprehensive Transplant Institute
University of Alabama at Birmingham, Birmingham, AL
Arthur Matas, MD  
Professor, Department of Surgery  
Director, Renal Transplant Program  
University of Minnesota, Minneapolis, Minnesota

Michael Mittelman  
Patient Representative/Speaker

Robert A. Montgomery, MD, DPhil  
Professor of Surgery  
Director, NYU Langone Transplant Institute  
New York, New York

Peter Nickerson, MD  
Distinguished Professor, Internal Medicine and Nephrology  
Flynn Family Chair in Renal Transplantation  
University of Manitoba, Winnipeg, Manitoba

Anat Roitberg-Tambur, DMD, PhD  
Director, Transplant Immunology Laboratory  
Comprehensive Transplant Center  
Research Professor  
Feinberg School of Medicine, Northwestern University  
Chicago, IL

Milagros Samaniego-Picota, MD  
Professor, Internal Medicine  
Medical Director, Kidney and Kidney Pancreas Transplantation  
University of Michigan, Ann Arbor, MI

Mark D. Stegall, MD  
General Surgeon  
Mayo Clinic, Rochester, MN

Ergun Velidedeoglu, MD  
Medical Officer, DTOP  
CDER, FDA, Silver Spring, MD

Yan Wang, PhD  
Team Lead, Statistics, Office of Biostatistics, Division of Biometrics IV  
CDER, FDA, Silver Spring, MD

Chris Wiebe, MD  
Assistant Professor of Internal Medicine  
University of Manitoba, Winnipeg, Canada
E. Steve Woodle, MD  
Professor, Chief-Division of Transplant Surgery  
University of Cincinnati, Cincinnati, OH

Disclosures

Dr. Alloway receives grant support from Novartis, Onyx, GSK, Prolong, Bristol-Myers Squibb, Genzyme, and Sanofi. She serves on an advisory board for Genzyme, Sanofi, and speaker’s bureau for Genzyme, Sanofi and Veloxis.

Dr. Chawla provides consultation for Nxstage Medical, Astute Medical, and Baxter Medical, and is on Sabbatical from La Jolla Pharmaceutical.

Dr. Colvin is a consultant to Shire Pharmaceuticals and Alexion Pharmaceuticals.

Dr. Djamali has received research funding from BMS (Investigator Initiated Trial), Takeda Millennium (Investigator Initiated Trial) and NIDDK (R01).

Dr. Gaston has served as a consultant during the past 12 months for CTI Clinical Trials, Immucor, Novartis and Veloxis.

Dr. Mark Haas serves as a paid consultant to Shire ViroPharma and AstraZeneca.

Dr. William Irish is a full time employee of CTI Clinical Trial and Consulting Services.

Dr. Knoll has received research grant support from Astellas Canada and the Canadian Institutes of Health Research.

Dr. Mannon has received grant support from Alexion, Astellas, Quark Pharmaceuticals and Care Dx (in addition to Honorarium with CareDx).

Dr. Matas serves as a PI and receives grant support from National Institute of Health, Astellas, Novartis, Bristol-Myers Squibb, and Sanofi. In the last year Dr. Matas participated in advisory board meetings to Astellas, Novartis and Veloxis and received an honorarium. Dr. Matas had a talk sponsored by Sanofi and received an honorarium and travel expenses.

Dr. Nickerson serves as a consultant for Astellas, GSK, Novartis and ViatEric.

Dr Roitberg-Tambur is a consultant to Astellas and directs the core lab for the Astound clinical trial, Dr Roitberg-Tambur is also a consultant to CSL Behring and has received consultation fees.
Dr. Stegall has served on the Ad Board for Novartis, Roche, and Astellas. Dr. Stegall also received a Mayo Contract—Transplant Genomics, Inc.

Dr. Woodle has served as a consultant, speaker and received research grants from Sanofi; received research grants from Bristol Myers Squibb; research grants from Amgen and research grants from Glaxo Smith Kline.